Sabena Sultan
Direttore Tecnico/Scientifico/R&S presso Cell Therapy Ltd.
Profilo
Sabena Sultan is currently the Director & Global Head-Research at Cell Therapy Ltd.
Prior to this, he worked as a Principal Investigator at University College London and King's College London.
He holds a doctorate degree from Imperial College London.
Posizioni attive di Sabena Sultan
| Società | Posizione | Inizio |
|---|---|---|
Cell Therapy Ltd.
 Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Direttore Tecnico/Scientifico/R&S | - |
Precedenti posizioni note di Sabena Sultan
| Società | Posizione | Fine |
|---|---|---|
| University College London | Corporate Officer/Principal | - |
| King's College London | Corporate Officer/Principal | - |
Formazione di Sabena Sultan
| Imperial College London | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 1 |
|---|---|
Cell Therapy Ltd.
Cell Therapy Ltd. BiotechnologyHealth Technology Cell Therapy Ltd. produces regenerative medicines using adult stem cells to treat heart failure. Its product HeartCel, a stem cell therapy that offers improved outcomes for heart failure patients by reducing the size of heart scar, improving heart function, quality of life and reducing mortality. The firm develops therapies based on the adult mesenchymal stromal cells technology platform. The firm’s regenerative therapies will focus on curing the cause of the disease, rather than only treating the symptoms. The company was founded in 2009 by Martin John Evans and Ajan Trevor Reginald and is headquartered in Cardiff, the United Kingdom. | Health Technology |
- Borsa valori
- Insiders
- Sabena Sultan
